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ABSTRACT 
 
Background: The price per milligram for most statin medications decreases at higher strengths, which provides an 
economic incentive to split tablets. We sought to determine the frequency with which statin tablets are split, and to 
evaluate factors associated with this practice. 
Methods: We obtained prescription claims data for statins from the BC Ministry of Health for the period Jan. 1, 1996, 
to Dec. 31, 2006. We estimated the number of tablets per day, based on the ratio of the number of tablets to days-
supply in each prescription, to estimate the frequency with which splitting occurred with each statin. We used multi-
variable logistic regression to assess patient and physician characteristics and the level of public drug plan coverage as-
sociated with tablet splitting. To estimate related cost savings, we used information on drug costs and quantities of 
dispensed statins reported by pharmacies. 
Results: During the 11-year study period, we estimated that tablet splitting occurred in 2.6% of 7.2 million statin pre-
scriptions. There was an increasing trend in the practice over time, to 4.5% of prescriptions in 2006. Lovastatin was 
the only scored tablet and was the most likely to be split, followed by rosuvastatin and atorvastatin. Fifty percent of the 
prescriptions in which tablet splitting occurred were prescribed by only 7.9% of the routine statin prescribers (i.e., > 10 
statin prescriptions over the study period). Specialists were less likely than general practitioners to prescribe statins 
that were subsequently split (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.40–0.46). Statin prescriptions that 
were fully covered by the public drug plan were half as likely as those with no such coverage to involve tablet splitting 
(OR 0.48, 95% CI 0.44–0.92). Having no public drug coverage, having a low annual household income and being fe-
male were patient factors found to be positively associated with tablet splitting. In 2006, the cost savings associated 
with tablet splitting was $2.3 million. 
Interpretation: The frequency of tablet splitting in statin prescriptions in British Columbia was low but increased over 
time. It varied between patients, physicians and different levels of insurance coverage. In the final study year, 94.5% of 
the statin prescriptions were dispensed at strengths for which a tablet of twice the strength was available and could 
have been split, which suggests a potentially enormous cost savings. 
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OR  MANY  PRESCRIPTION  DRUGS,  THE  PRICE  
per milligram decreases substantially at higher 
strengths. This circumstance provides an incen-
tive to reduce costs by splitting higher-dose tablets to ob-
tain  a  prescribed  lower  dose  at  a  substantially  lower 
price. In the United States, some major drug plan insur-
ers have implemented tablet-splitting programs that tar-
get statins.1,2 Tablet splitting has been shown to reduce 
prescription costs substantially1,3,4 without negatively af-
fecting laboratory outcomes  or compliance.4–6 In addi-
tion, patients have found tablet splitting to be simple and 
acceptable.4,7 
  Little  is  known  about  patient  and  physician 
characteristics  associated  with  tablet  splitting  or  how 
common  the  practice  is  in  Canada.  When  looking  at 
aggregated  2005  data  from  the  province  of  British 
Columbia, we noticed that the mean number of tablets 
per prescription varied among the statins. Since statins 
are  used  only  for  long-term  prevention  of  myocardial 
infarction  and  stroke,  we  thought  that  the  most  likely 
reason  for  this  variation  was  that  some  patients  were 
splitting tablets. We looked for the most specific method 
to measure tablet splitting and used that to examine the 
frequency  and  predictors  of  tablet  splitting  in  British 
Columbia.  Public  and  private  insurers  in  the  province 
have  no  programs  requiring  or  encouraging  tablet 
splitting, which means that the initiative for this practice 
comes solely from patients, pharmacists and physicians.  
Methods 
Data  source.  We  obtained  prescription  records  from 
the  PharmaNet  database,  which  contains  all  prescrip-
tions dispensed at community pharmacies in British Co-
lumbia.8 We linked records in PharmaNet to information 
in  the  BC  Ministry  of  Health’s  databases  for  premium 
subsidy income level and medical services registration. 
These  latter  databases  were  used  to  determine  patient 
income level and eligibility for provincial health cover-
age. 
 
Study population. With some exceptions, the source 
population  included  all  people  who  were  residents  of 
British Columbia at any time between Jan. 1, 1996, and 
Dec.  31,  2006.  We  excluded  federally  insured  patients 
(about 4% of the provincial population) because we did 
not  have  access  to  their  prescribing  data.  We  also  ex-
cluded patients who were receiving social income assis-
tance,  because  concurrent  changes  in  income  support 
policies made that population unstable for analysis, and 
residents  of  nursing  homes,  because  their  medication 
use  was  expected  to  be  highly  regulated.  The  source 
population,  after  exclusions,  numbered  4.1  million  in 
2006  (Statistics  Canada,  CANSIM  database).  We  in-
cluded all patients from the source population who re-
ceived a statin from a community pharmacy. 
 
Prescription drug coverage. Residents aged 65 years 
and older were fully covered by the provincial drug plan 
for  prescription  ingredient  costs  before  January  2002 
but still had to pay the first Cdn$200 in dispensing fees 
each year. Between January 2002 and April 2003, pa-
tients over 65 paid a new charge of $25 per prescription 
($10 for patients whose medical services premiums were 
subsidized by the province). Residents under 65 years of 
age were covered  for  prescription ingredient costs and 
dispensing fees under a public plan that included a de-
ductible and a co-insurance payment. Coverage for fami-
lies of all ages was combined into a single policy on May 
1, 2003. The new policy included an income-based de-
ductible and a 25% or 30% co-insurance payment. Full 
coverage for patients in nursing homes and those receiv-
ing social income assistance was continued. Data on pri-
vate drug insurance coverage were unavailable. 
 
Quantification of statin splitting. Each PharmaNet 
record includes the number of tablets and days-supply of 
medication dispensed. We used the ratio of these 2 val-
ues to estimate the number of tablets per day. We calcu-
lated  relative  frequencies  for  the  tablets:days-supply 
ratios, in ratio intervals of 0.1. For example, a prescrip-
tion  with  a  tablets:days-supply  ratio  of  0.25  would  be 
counted in the interval “0.2 to < 0.3.” Prescriptions with 
ratios exactly equal to 0.5 were presumed to have been 
split. Prescriptions with ratios exactly equal to 1.0 were 
presumed to have not been split. This method of estimat-
ing splitting in claims data has been applied previously.3 
Table 1 shows the statins and splitting combinations that 
we analyzed. 
We  assessed  factors  associated  with  tablet  splitting 
among new users of statins. One benefit of studying first-
time prescriptions to new users was that within-patient 
clustering was not a factor. We defined new users as pa-
tients who had not received another statin prescription 
for at least 2 years before the current prescription. We 
compared new users who were presumed to be splitting 
tablets (tablets:days-supply ratio = 0.5) with those who 
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were presumed to not be splitting 
tablets  (ratio  =  1.0).  New  users 
whose  tablets:days-supply  ratio 
was other than 0.5 or 1.0 were ex-
cluded from the analysis to maxi-
mize the specificity of the outcome. 
 
Statistical  analysis.  We  ana-
lyzed  potential  factors  associated 
with  tablet  splitting  using  logistic 
regression analysis. We used gen-
eralized  estimating  equations 
(GEEs)  to  adjust  standard  errors 
for  correlations  between  repeated 
observations  for  the  same  pre-
scribers.9  Hence,  the  new-users 
analysis was implicitly adjusted for 
clustering  at  the  patient  level  by 
analyzing  each patient  only  once, 
and  explicitly  at  the  physician  level  by  using  the  GEE 
method. The GEEs assumed an exchangeable correlation 
matrix. Odds ratios and corresponding 95% confidence 
intervals were estimated using the Genmod procedure in 
SAS, version 9.1 (SAS Institute, Inc., Cary, North Caro-
lina). We included the following variables in the analysis: 
patient age; sex; annual household income, in Canadian 
dollars (high: ≥ $28 000; moderate: $20 000 to < $28 
000; and low:  < $20 000);10 level of public drug plan 
coverage  for  the  prescription  (full,  partial,  none);  pre-
scriber specialty (specialist or  general  practitioner);  an 
indicator variable for whether the prescriber’s last statin 
prescription involved tablet splitting; type of statin; an 
indicator  variable  for  whether  the  smallest  strength  of 
statin was dispensed; number  of  weeks-supply of drug 
dispensed;  and  type  of  pharmacy  (independent,  chain, 
other). In a secondary analysis, we performed the same 
logistic regression involving all statin patients (new plus 
continuing  users)  using  the  same  variables.  In  that 
analysis, we used GEEs to adjust standard errors for cor-
relations between repeated observations for the same pa-
tients.  Our  computer  programs  were  unable  to 
simultaneously adjust for clustering within patients and 
physicians because the data set was too large. 
  Ingredient cost savings from tablet splitting were es-
timated for the 2006 calendar year. First, we estimated 
the daily difference in cost between a split tablet and a 
whole tablet by subtracting from the cost of a whole tab-
let (e.g., one 10-mg tablet of atorvastatin) the cost of half 
a tablet of a higher strength (e.g., half of a 20-mg tablet 
of  atorvastatin).  We  defined  the  cost  per  tablet  as  the 
mean  dollar  amount  claimed  per  tablet  in  the  Phar-
maNet database in 2006.  Next,  we estimated the total 
ingredient  cost  savings  by  multiplying  the  daily  cost  
 
Table 2: Tablets:days-supply ratios for statin 
prescriptions dispensed in British Columbia, 
1996–2006 
Ratio*  
No. of statin pre-
scriptions† 
Relative fre-
quency, % 
< 0.1  319  0.00 
0.1 to < 0.2  710  0.01 
0.2 to < 0.3  6 311  0.09 
0.3 to < 0.4  4 584  0.06 
0.4 to < 0.5  2 852  0.04 
0.5  189 182  2.62 
> 0.5 to < 0.6  6 197  0.09 
0.6 to < 0.7  2 944  0.04 
0.7 to < 0.8  2 054  0.03 
0.8 to < 0.9  1 363  0.02 
0.9 to < 1.0  2 206  0.03 
1.0  6 731 886  93.41 
> 1.0  256 465  3.56 
Total  7 207 083  100.00 
*For prescriptions with a ratio of 0.5, tablet splitting was presumed; for 
prescriptions with a ratio of 1.0, no tablet splitting was presumed. 
†Excludes prescriptions to nonresidents, residents of long-term care fa-
cilities and patients receiving social income assistance. 
Table 1: Statins and splitting combinations included in the analysis 
  Daily dose* 
Statin†  2.5 mg‡  5 mg‡  10 mg‡  20 mg  40 mg 
Atorvastatin 
–  0.5 × 10 mg  0.5 × 20 mg  0.5 × 40 mg  0.5 × 80 mg 
Fluvastatin§ 
– 
–  0.5 × 20 mg  0.5 × 40 mg 
– 
Lovastatin 
– 
–  0.5 × 20 mg  0.5 × 40 mg 
– 
Pravastatin 
–  0.5 × 10 mg  0.5 × 20 mg  0.5 × 40 mg 
– 
Rosuvastatin  0.5 × 5 mg  0.5 × 10 mg  0.5 × 20 mg  0.5 × 40 mg 
– 
Simvastatin  0.5 × 5 mg  0.5 × 10 mg  0.5 × 20 mg  0.5 × 40 mg  0.5 × 80 mg 
*The lowest strengths available were 5 mg (rosuvastatin, simvastatin), 10 mg (atorvastatin, pravastatin) and 20 mg 
(fluvastatin, lovastatin). The largest strengths available were 40 mg (pravastatin, lovastatin, rosuvastatin) and 
80 mg (atorvastatin, fluvastatin, simvastatin). Strengths not included in the analysis are denoted by “–.” 
†Between Oct. 16, 2006, and Oct. 15, 2007, the median costs per tablet dispensed for statins in the PharmaNet 
database were (generic price in parentheses): atorvastatin 10 mg = $1.78, 20 mg = $2.23, 40 mg = $2.39, 80 mg = 
$2.39; fluvastatin 20 mg = $0.86, 40 mg = $1.20; lovastatin 20 mg = $1.98 ($1.11), 40 mg = ($2.11); pravastatin 
10 mg = $1.67 ($0.95), 20 mg = $1.97 ($1.12), 40 mg = $2.37 ($1.35); rosuvastatin 5 mg = $1.38, 10 mg = $1.46, 
20 mg = $1.82, 40 mg = $2.13; simvastatin 5 mg = $1.03 ($0.60), 10 mg = $2.04 ($1.12), 20 mg = $2.52 ($1.39), 
40 mg = $2.52 ($1.41), 80 mg = $2.52 ($1.44). 
‡Prescriptions in which tablets were split for daily doses less than the lowest available strength of whole tablets 
were included in the analysis (atorvastatin 0.5 × 10 mg, lovastatin 0.5 × 20 mg, pravastatin 0.5 × 10 mg, rosuvas-
tatin 0.5 × 5 mg and simvastatin 0.5 × 5 mg). 
§Fluvastatin is a capsule or extended-release tablet and should not be split. R e s e a rc h                                                                                                                                               D o rm u t h   et al 
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  Fig. 1: Proportion of 
statin prescriptions in 
British Columbia that     
involved tablet splitting, 
1996–2006. 
 
difference for each statin by the 
total  number  of  days-supply 
dispensed for that statin in split 
tablets. We multiplied the daily 
cost  difference  by  20%  of  the 
eligible days-supply to estimate 
the potential savings from tablet 
splitting  in  20%  of  prescrip-
tions. We arbitrarily chose 20% 
as  a  plausible  rate  that  could  
result  from  a  voluntary  tablet-
splitting  program  including  
financial incentives from a drug 
plan.  To  estimate  potential  savings  from  splitting  in 
100% of prescriptions, the theoretical maximum savings, 
we used 100% of the eligible days-supply. We excluded 
from the cost-savings analysis  prescriptions  for  fluvas-
tatin (because it is a capsule and thus should not be split) 
and  statins  already  dispensed  in  the  highest  available 
strength.  We  also  excluded  prescriptions  with  a  tab-
lets:days-supply ratio other than 0.5 or 1.0. No adjust-
ments  to  cost-savings  estimates  were  made  for  drug 
waste, the cost of tablet splitters, or additional work by 
pharmacists and patients.    
Results 
A total of 7.2 million statin prescriptions were dispensed 
during the 11-year study period. Of these prescriptions, 
we estimated that 2.6% involved tablet splitting (Table 2) 
and that there was an increasing trend in tablet splitting 
over time, to 4.5% of prescriptions in 2006 (Fig. 1). In 
the last year of the analysis (2006), 94.5% of the statin 
prescriptions were dispensed at strengths for which tab-
lets of twice the strength were available and could have 
been split. Of the remaining prescriptions, 0.8% were for 
fluvastatin (a capsule), and 4.7% were dispensed in the 
highest  available  strength.  Also  in  2006,  rosuvastatin 
and atorvastatin were the most likely statins to be split 
(7.4% and 5.2% of prescriptions, respectively), whereas 
pravastatin (1.4%) and fluvastatin (a capsule, 0.5%) were 
the  least  likely  to  be  split.  Lovastatin,  the  only  statin 
available in scored tablets, was split at a fairly constant 
rate of 2.5%–3% over the study period. 
Of the prescriptions in which tablet splitting occurred, 
50% were prescribed by only 7.9% of routine statin pre-
scribers (> 10 statin prescriptions over the study period). 
These prescribers did not differ significantly in terms of 
their patients’ age, sex, household income level, level of 
public drug plan coverage or statin type. The proportion 
of  general  practitioners  was  higher  among  these  pre-
scribers  (94.0%)  than  among  those  whose  statin  pre-
scriptions involved less frequent tablet splitting (80.2%). 
The 7.9% of routine statin prescribers wrote over 4 times 
as  many  statin  prescriptions  on  average  as  the  other 
92.1% of prescribers. 
There were 312 760 statin prescriptions dispensed to 
new users. These patients had a mean age of 62.9 years, 
44.8% were women, and 21.6% had low annual house-
hold incomes (< $20 000) (Table 3). The proportion of 
patients who had partial drug plan coverage was similar 
among  those  who split  tablets and those  who did  not. 
This was not true for patients who received full coverage 
(13.8% of splitters v. 24.8% of non-splitters) or for those 
who had no coverage (61.0% of splitters v. 50.2% of non-
splitters). 
The results of the logistic regression analysis of predic-
tors of tablet splitting are shown in Table 4. The likelihood 
of  tablet  splitting  among  new  statin  users  increased  
significantly  with  age  until  65,  when  it  decreased  
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Table 3: Characteristics of new users dispensed statin prescriptions in British Columbia,  
by tablet-splitting status, 1998–2006 
Characteristic 
Split tablets, % 
(n = 10 213) 
Whole tablets, % 
(n = 302 547)  Difference (95% CI)*  p value† 
Patient characteristics                     
Age, yr, mean  61.1  63.0  −1.9  (−2.2 to −1.7)  < 0.001 
Sex, female  4 918  (48.2)  135 129 (44.7)  3.5   (2.5 to 4.5)  < 0.001 
Annual household income               
< $20 000  2 502  (24.5)  65 183 (21.5)  3.0  (2.1 to 3.8)  < 0.001 
$20 000 to < $28 000  528  (5.2)  11 831  (3.9)  1.3  (0.8 to 1.7)  < 0.001 
≥ $28 000  7 183  (70.3)  225 534 (74.5)  −4.2 (−5.1 to −3.3)  < 0.001 
Public drug plan coverage               
Partial  2 580  (25.3)  75 508 (25.0)  0.3 (−0.6 to 1.2)  0.484 
Full  1 405  (13.8)  75 088 (24.8)  −11.0 (−11.6 to −10.3)  < 0.001 
None  6 228  (61.0)  151 952 (50.2)  10.8  (9.8 to 11.7)  < 0.001 
Statin dispensed               
Atorvastatin  6 311  (61.8)  190 802 (63.1)  −1.3 (−2.2 to −0.3)  0.009 
Fluvastatin  17  (0.2)  4745  (1.6)  −1.4 (−1.5 to −1.3)  < 0.001 
Lovastatin  322  (3.2)  6006  (2.0)  1.2  (0.8 to 1.5)  < 0.001 
Pravastatin  267  (2.6)  20 939  (6.9)  −4.3 (−4.6 to −4.0)  < 0.001 
Rosuvastatin  1 986  (19.4)  20 932  (6.9)  12.5 (11.8 to 13.3)  < 0.001 
Simvastatin  1 310  (12.8)  59 124 (19.5)  6.7 (−7.4 to −6.1)  < 0.001 
Pharmacy type used               
Independently owned (< 3 locations)  1 935  (18.9)  49 648 (16.4)  2.5  (1.8 to 3.3)  < 0.001 
Chain (≥ 3 locations)  8 272  (81.0)  252 502 (83.5)  −2.5 (−3.2 to −1.7)  < 0.001 
Other facility (e.g., physician’s office)  6  (0.1)  397  (0.1)  −0.1 (−0.1 to 0.0)  0.045 
Note: CI = confidence interval. 
*Difference in proportion of patients in the split-tablet group compared with whole-tablet group (except for age, which was reported as 
the difference in mean age). Except for age, CIs were estimated assuming a binomial distribution. The CI for the difference in mean age 
was estimated using a standard normal distribution. 
†p values were based on a standard normal distribution (difference in mean age) or a χ
2 distribution with 1 degree of freedom (all other 
differences). 
 
significantly. Female patients were 23% more likely than 
male patients to split tablets (p < 0.001). Tablet splitting 
was  51%  more  likely  to  occur  among  patients  in  low-
income households than among those in higher income 
groups (p < 0.001). It was less likely to occur with pre-
scriptions covered by the public drug plan than with pre-
scriptions not covered by the drug plan (29% less likely for 
partially covered claims and 52% less likely for fully cov-
ered  claims;  p < 0.001).  Tablet  splitting  was  4  times 
more  likely  to  occur  if  the  prescribing  physician’s  last 
statin prescription had involved tablet splitting than if it 
had  not  (p < 0.001).  The  likelihood  of  tablet  splitting 
was  also  significantly  associated  with  the  type  of  statin 
prescribed and the number of weeks-supply of drug dis-
pensed. 
  The  estimated  ingredient  cost  savings  from  tablet 
splitting in 2006 was $2.35 million (Table 5), or $18 per 
statin-patient. The potential cost savings from splitting 
tablets in 20% of eligible prescriptions was $10.5 million 
dollars. The potential savings from splitting all eligible 
prescriptions was $51.4 million.  
 
Interpretation 
Our study showed that tablet splitting in statin prescrip-
tions was associated with patient and physician factors 
and with the level of coverage in the public drug plan. An 
increasing trend in tablet splitting over the study period 
coincided  with  market  penetration  of  more  expensive 
statins  (atorvastatin  and  rosuvastatin)  and  with  in-
creases in levels of cost-sharing in the public drug plan 
in 2002 and 2003. Those policies are described in detail 
elsewhere.11,12 
The relation between patient age and tablet splitting 
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Table 4: Factors associated with tablet splitting 
  New statin users*  All statin users† 
Factor 
Crude 
OR 
Adjusted OR 
(95% CI)‡ 
Crude 
OR 
Adjusted OR 
(95% CI)§ 
Public drug plan coverage            
None  1.55  1.00 (ref)  2.20  1.00 (ref) 
Partial  1.02  0.71 (0.67–0.75)  0.92  0.57 (0.55–0.59) 
Full  0.48  0.48 (0.44–0.52)  0.39  0.35 (0.34–0.37) 
Physician characteristics           
Specialist  0.66  0.43 (0.40–0.46)  0.92  0.56 (0.54–0.59) 
Last statin prescription involved tablet 
splitting  3.64  4.24 (4.01–4.49)  2.77  3.21 (3.13–3.29) 
Statin dispensed           
Atorvastatin  0.95  1.00 (ref)  1.77  1.00 (ref) 
Rosuvastatin  3.25  1.22 (1.15–1.30)  2.54  1.16 (1.10–1.22) 
Lovastatin  1.61  2.18 (1.93–2.47)  1.01  1.17 (1.09–1.26) 
Simvastatin  0.61  0.37 (0.34–0.39)  0.54  0.37 (0.35–0.39) 
Pravastatin  0.36  0.23 (0.20–0.26)  0.28  0.20 (0.18–0.22) 
Fluvastatin  0.11  0.05 (0.03–0.08)  0.17  0.09 (0.08–0.12) 
Strength and supply           
Smallest strength of tablet dispensed  0.46  0.30 (0.29–0.32)  0.81  0.50 (0.48–0.52) 
No. of weeks supply dispensed  1.08  1.08 (1.08–1.09)  1.07  1.08 (1.07–1.08) 
Pharmacy type used           
Independently owned (> 3 locations)  1.19  1.00 (ref)  1.02  1.00 (ref) 
Chain (≥ 3 locations)  0.96  0.95 (0.91–0.99)  1.08  0.96 (0.93–0.99) 
Other facility (e.g., physician’s office)  0.45  0.55 (0.24–1.24)  0.51  0.60 (0.35–1.01) 
Note: OR = odds ratio, CI = confidence interval, ref = reference group. 
*Patients newly prescribed a statin from July 1, 1998, to Dec. 31, 2006. 
†Includes only prescriptions with a tablet:days-supply ratio of 0.5 (tablet splitting presumed, n = 184 298) or 1.0 (no tablet splitting pre-
sumed, n = 6 469 618). Statins prescribed from July 1, 1996 to Dec. 31, 2006. 
‡Estimated from multivariable generalized estimating equations (GEEs) that adjusted for all other covariates in the table and for pre-
scriber-level clustering. 
§Estimated from multivariable GEEs that adjusted for all other covariates in the table and for patient-level clustering. 
 
British Columbia was more generous for patients over 65 
years of age than for younger patients. A correlation be-
tween better public coverage and higher age most cer-
tainly accounted for some of the lower relative likelihood 
of tablet splitting observed among older patients. Other 
factors such as frailty, cognitive impairment and concur-
rent use of other medications, which could make tablet 
splitting  inappropriate  and  which  are  more  common 
among older patients, could also have contributed to the 
lower relative likelihood of tablet splitting. 
Our  observation  that  patients  in  low-income  house-
holds  were  more  likely  than  those  in  higher-income 
households  to  split  tablets  was  expected,  since  lower-
income people have a greater need to save money. How-
ever, we could not determine  whether  the initiative  to 
split tablets for this reason was initiated by the physi-
cians  or  the  patients.  Females  were  more  likely  than 
males to split tablets. A test of interaction between fe-
male sex and income level showed that the combined ef-
fect  was  greater  than  the  independent  effects;  this 
suggested  that,  at  any  given  income  level,  female  pa-
tients were more sensitive than male patients to the cost. 
This observation is similar to that from another study in 
British Columbia on switching drugs as a consequence of 
reference pricing.13 
Of the statin prescriptions, 4% showed a tablets:days-
supply ratio other than 0.5 (tablet splitting presumed) or 
1.0 (no tablet splitting presumed). This could have been 
due to data-entry errors at the pharmacy or to tablets be-
ing split more than once. Our analysis of fluvastatin, a 
statin  that  should  not  be  split  because  it  is  a  capsule, 
showed that splitting occurred in about 0.5% of prescrip-
tions  each  year  (Fig.  1).  This  result  could  indicate  the 
proportion  of  prescriptions  that  our  algorithm  falsely R e s e a rc h                                                                                                                                               D o rm u t h   et al 
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Table 5: Potential ingredient cost savings from splitting statin tablets in British Columbia, 2006 
Frequency of tablet splitting;  
potential cost savings from splitting, $* 
Statin 
Total ingredient 
cost expenditure, $ 
4.5% of pre-
scriptions† 
20% of pre-
scriptions‡ 
100% of prescrip-
tions§ 
Dispensing 
fees in 2006, $ 
Atorvastatin    83 499 620  1 601 358   6 932 675   35 657 790   5 848 746  
Lovastatin      2 595 963  745   21 978   121 441   241 325  
Pravastatin      5 253 757  25 356   270 199   1 324 925   555 662  
Rosuvastatin    12 215 068  458 421   1 276 057   4 798 244   1 125 060  
Simvastatin    20 208 116  258 915   1 944 698   9 513 963   2 195 822  
All  123 772 525  2 344 795   10 445 607   51 416 363   9 966 615  
* The estimated maximum savings on drug ingredient costs assuming no drug waste, no extra pharmacist remuneration and the same  
market share (by claim volume) for each statin. 
† The observed percentage of statin prescriptions in 2006 in which tablet splitting was presumed. 
‡ An arbitrarily chosen percentage of prescriptions involving tablet splitting that might be expected from a voluntary tablet-splitting program   
including financial incentives from a drug plan. 
§ Maximum potential cost savings assuming tablet splitting occurred in all eligible prescriptions. Prescriptions for fluvastatin (0.8% of statin 
prescriptions) and for statins already dispensed in the highest available strength (4.7% of prescriptions) were considered ineligible for  
splitting. 
 
identified  as  split.  If  so  interpreted,  the  percentage  of 
statin prescriptions in which splitting occurred in 2006 
may have been 4% instead of 4.5%. 
We  were  unable  to  determine  from  the  claims  data 
whether any given instance of tablet splitting was initi-
ated  by  the  physician,  the  patient  or  the  pharmacist. 
However,  3  results  in  our  analysis  suggest  that  physi-
cians influenced decisions to split tablets. First, most of 
the prescriptions that involved splitting were prescribed 
by only 7.9% of routine statin prescribers. Second, the 
likelihood of tablet splitting was 4-fold higher if the phy-
sician’s last statin prescription involved tablet splitting. 
Third, tablet splitting was less likely to occur with statins 
prescribed by specialists than with those prescribed by 
general practitioners, perhaps because general practitio-
ners knew more about their patients’ ability to pay for 
drugs. Our observation that tablet splitting did not occur 
in most physicians’ statin prescriptions but that it was a 
frequent practice in some physicians’ prescriptions sug-
gests that educational initiatives could increase its fre-
quency. Educational interventions could also be directed 
at pharmacists, since they too have the discretion to split 
tablets. 
The  generalizability  of  our  results  to  other  jurisdic-
tions  is  unknown.  Tablet  splitting  seems  to  be  more 
common in at least some jurisdictions such as the Neth-
erlands14 and Germany.15 The matter of generalizability 
is complicated by the fact that drug insurance plans and 
drug  prices  vary  substantially  around  the  world.  Our 
analysis  also  lacked  information  on  private  insurance 
coverage, which likely led to an underestimation of the 
effect of public drug plan coverage on tablet splitting. Pa-
tients with private coverage would have less of an incen-
tive  to  split  tablets  than  patients  with  no  coverage. 
Despite these limitations, the direction of our effect es-
timates for insurance coverage should still translate  to 
patients in other jurisdictions who are subject to flat or 
substantially flat prices for statins (e.g., the price for one 
40-mg tablet of atorvastatin is substantially less than the 
cost of two 20-mg tablets) and who pay a percentage of 
their prescription costs out of pocket. 
The PharmaNet data we obtained  for our study did 
not  include  data  for  prescriptions  dispensed  in  acute 
care hospitals  or  prescriptions to  federally  insured  pa-
tients  (e.g.,  Status  Indians,  prisoners,  Royal  Canadian 
Mounted Police and Canadian Armed Forces), who com-
prised about 4% of the population. Since these patients 
were mostly younger and accounted for a small portion 
of the total population, we do not believe that excluding 
them  substantially  affected  our  results  or  conclusions. 
Misclassification  in  our  study  was  likely  very  rare  be-
cause  the  PharmaNet  system  performs  data-quality 
checks when prescriptions are processed. The complete-
ness and accuracy of the BC Ministry of Health databases 
are probably comparable to those of similar databases in 
other  North  American  jurisdictions  that  have  been 
evaluated for quality.16–20 
For drug insurance plans that include a patient cost-
sharing  component,  savings  from  tablet  splitting  can 
benefit both the patients and the plan. In addition, drug R e s e a rc h                                                                                                                                               D o rm u t h   et al 
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plans could influence tablet splitting by using financial 
incentives. Some plans have recognized this  possibility 
and have adopted voluntary tablet-splitting programs. In 
the Veterans Affairs health care system in Palo Alto, Cali-
fornia, statin drug costs were lowered by 39%, including 
the cost of tablet splitters, among patients volunteering 
for  a  tablet-splitting  program.1  The  savings  were  large 
even  though  Veterans  Affairs  purchased  drugs  below 
wholesale prices. In that program, pharmacists were not 
compensated for any additional time they spent splitting 
tablets  and  educating  patients;  however,  additional 
pharmacist  costs  would  easily  have  been  covered  by  a 
portion of the savings. In British Columbia, our analysis 
showed that $145.3 million was spent on statins in 2006; 
$123.8 million  of  this  amount  was  for  prescriptions  to 
patients who were not taking the highest-strength tablet 
or fluvastatin, and who were not receiving social income 
assistance  or  residing  in  a  nursing  home.  Pharmacists 
charged $12.2 million in dispensing  fees for those pre-
scriptions. Even if dispensing fees were doubled for pre-
scriptions that involved tablet splitting, the cost  would 
be less than one-fifth the savings in ingredient costs. Re-
alistically, most patients can split their own statin tab-
lets.  Other  costs  related  to  splitting,  such  as  tablet 
splitters and ingredient waste, can also be expected to be 
minor compared with the savings on ingredient costs. 
  Although most statins are not scored, our experience 
with prescribing statins in split doses — by having pa-
tients take half a tablet at bedtime and the other half the 
following night — suggests that it is a simple and safe 
procedure for most patients, although some may not be 
good candidates because  of frailty or cognitive impair-
ment. Our analysis showed that tablet splitting is becom-
ing  more  popular  and  that  potential  savings  are 
enormous as more physicians, pharmacists and patients 
become aware of this simple cost-saving measure. Pro-
vincial and territorial governments seeking ways to lower 
costs in their drug plans could learn from innovative ex-
amples in other jurisdictions and implement programs 
designed to encourage tablet splitting. 
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